Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 12:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Focal Segmental Glomerulosclerosis
Interventions
No intervention
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Cincinnati, Ohio • Pittsburgh, Pennsylvania
Conditions
Glomerulonephritis, Nephrotic Syndrome
Interventions
Dexamethasone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Focal Segmental Glomerulosclerosis
Interventions
ManNAc
Drug
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years to 115 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Recruiting No phase listed Observational

Proteinuria in Pre and Post Transplant

NCT01094327
Conditions
Proteinuria
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
Up to 25 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2026
U.S. locations
1
States / cities
Miami, Florida
Conditions
Focal Segmental Glomerulosclerosis, Minimal Change Disease, FSGS, MCD
Interventions
Biospecimen collection, Data collection
Other
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Kidney Diseases, Glomerulosclerosis, Focal Segmental Nephrosis, Lipoid Urologic Disease, Glomerulonephritis, Nephritis, Nephrosis
Interventions
GFB-887
Drug
Lead sponsor
Goldfinch Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
17
States / cities
Los Angeles, California • Northridge, California • Victorville, California + 14 more
Conditions
Focal Segmental Glomerulosclerosis
Interventions
Galactose
Drug
Lead sponsor
Northwell Health
Other
Eligibility
2 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Focal Segmental Glomerulosclerosis
Interventions
CCX140-B
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Torrance, California • Shreveport, Louisiana • Boston, Massachusetts + 2 more
Conditions
Focal Segmental Glomerulosclerosis (FSGS)
Interventions
PF-06730512
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
56
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 17 more
Conditions
Focal Segmental Glomerulosclerosis, Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Chronic Kidney Disease
Interventions
Cardiovascular Assessment, Renal Assessment, Genetic Evaluation
Other
Lead sponsor
Northwell Health
Other
Eligibility
6 Months to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New Hyde Park, New York
Conditions
Focal Segmental Glomerulosclerosis
Interventions
LIPOSORBER® LA-15 System
Device
Lead sponsor
Kaneka Medical America LLC
Industry
Eligibility
Up to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
12
States / cities
Loma Linda, California • Los Angeles, California • Wilmington, Delaware + 9 more
Conditions
Focal Segmental Glomerulosclerosis
Interventions
Voclosporin
Drug
Lead sponsor
Aurinia Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
21
States / cities
Denver, Colorado • Winter Park, Florida • Lawrenceville, Georgia + 17 more
Conditions
Focal Segmental Glomerulosclerosis, HIV-Associated Focal Segmental Glomerulosclerosis
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
19 Months and older
Enrollment
616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Focal Segmental Glomerulosclerosis
Interventions
RE-021 (Sparsentan), Irbesartan
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
8 Years to 75 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
28
States / cities
San Diego, California • Torrance, California • Denver, Colorado + 19 more
Conditions
Focal Segmental Glomerulosclerosis
Interventions
GC1008
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
San Francisco, California • Rochester, Minnesota • New Hyde Park, New York + 1 more
Conditions
Focal Segmental Glomerulosclerosis
Interventions
Praliciguat, Placebo
Drug · Other
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
23
States / cities
Chula Vista, California • Los Angeles, California • San Dimas, California + 19 more
Conditions
Focal Segmental Glomerulosclerosis
Interventions
Rituximab, Plasmapheresis
Drug · Procedure
Lead sponsor
University of Minnesota
Other
Eligibility
1 Year to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
12
States / cities
Tuscaloosa, Alabama • Davis, California • Chicago, Illinois + 8 more
Conditions
IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy
Interventions
Atrasentan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
14
States / cities
Glendale, California • Los Angeles, California • San Dimas, California + 11 more
Conditions
Fibrosis, Focal Glomerulosclerosis, Kidney Failure, Nephrotic Syndrome, Proteinuria
Interventions
Pirfenidone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Focal Glomerulosclerosis
Interventions
Sirolimus
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Healthy Volunteers
Interventions
GFB-887, Placebo
Drug
Lead sponsor
Goldfinch Bio, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Recruiting Not applicable Interventional

taVNS for FRNS in Children

NCT05588063
Conditions
Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis
Interventions
Transcutaneous auricular vagus nerve stimulation, Sham device
Device
Lead sponsor
Northwell Health
Other
Eligibility
3 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New Hyde Park, New York • Philadelphia, Pennsylvania
Completed Phase 2 Interventional Results available

Obinutuzumab in Primary FSGS

NCT04983888
Conditions
Primary Focal Segmental Glomerulosclerosis
Interventions
Obinutuzumab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy, Primary Membranous Nephropathy
Interventions
WAL0921, Placebo
Drug
Lead sponsor
Walden Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Denver, Colorado • Tamarac, Florida + 5 more